Oncoclínicas do Brasil Serviços Médicos (ONCO3) investor relations material

Executive summary

• Q1 2026 was marked by significant operational and financial pressures, including drug supply shortages, cash flow challenges, and stricter provisioning for doubtful accounts, prompting operational turnaround initiatives and creditor negotiations.

• Net revenue for Q1 2026 was R$1,160.8 million, a 22.3% decrease year-over-year, mainly due to lower gross revenue from drug shortages, higher provisions for doubtful accounts, and a more restrictive commercial policy.

• Gross profit dropped 51.6% to R$199.5 million, with gross margin falling from 27.6% to 17.2%.

• Net loss reached R$438.7 million, compared to a loss of R$132.0 million in Q1 2025, reflecting operational and financial pressures.

• Management discontinued prior managerial adjustments to provisions for doubtful accounts, impacting reported results.

Financial highlights

• Gross revenue for 1Q26 was R$1,458.4 million, down 12.0% year-over-year; net revenue was R$1,160.8 million, down 22.3% year-over-year.

• Adjusted EBITDA was negative R$49.2 million (margin -4.2%), compared to positive R$153.9 million (margin 10.3%) in 1Q25.

• Net revenue fell significantly quarter-over-quarter due to a one-time spike in PCLD (provision for doubtful accounts) to 14.3%.

• Gross margin, normalized for PCLD, dropped from 32.3% to 27.7% due to higher medication costs from local suppliers.

• Operating cash consumption was R$219.0 million, up from R$76.9 million in Q1 2025.

Outlook and guidance

• Management is focused on operational turnaround, cost optimization, asset sales, and may pursue inorganic initiatives to restore profitability and cash generation.

• Ongoing negotiations with creditors for further waivers, standstill agreements, and debt restructuring are critical for continuity.

• A new financing line of up to R$150 million was approved to support drug purchases and supply chain continuity.